Roberto Borea, Postdoctoral Research at Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, shared a post on LinkedIn about a paper he co-authored with colleagues published in ESMO Open:
“I am pleased to share our latest research validating the PREDICT v2.2 tool using pooled individual data from 6205 patients affected by early breast cancer across five Phase III randomized clinical trials (GIM/MIG).
Key Findings:
- Survival Underestimation: The tool underestimated 5-year overall survival (OS) by 5.6% and 10-year OS by 8.3%.
- Moderate Discrimination: The model demonstrated moderate accuracy with AUC values of 66.2% (5-year) and 63.9% (10-year).
- Subgroup Discrepancies: Underestimation was most pronounced in HER2+ disease (13.5% difference at 10 years), older patients (≥65), and those with obesity.
Conclusion:
While PREDICT remains a valuable resource, regular updates are essential to align with modern therapeutic advancements. Our findings suggest that incorporating factors could significantly improve prognostic accuracy in contemporary clinical practice.
I would like to extend my deepest gratitude to all the co-authors for their invaluable expertise and collaborative effort in making this study possible.”
Title: Validation of PREDICT tool v2.2 in patients with early-stage breast cancer enrolled in the GIM and MIG trials
Authors: R. Borea, E. Blondeaux, L. Carmisciano, L. Arecco, M. Perachino, F. Poggio, T. Ruelle, F. Luelli, M. de Laurentiis, G. Arpino, F. Puglisi, A. Fabi, S. Gori, P. Fregatti, M. Lambertini, L. Boni, L. Del Mastro
You can read the full article in ESMO Open.
More posts about Breast Cancer.